Purpose <p>To compare clinical characteristics and visual outcomes according to recurrence timing in eyes with myopic choroidal neovascularization (CNV) following anti-vascular endothelial growth factor (anti-VEGF) therapy.</p> Methods <p>This retrospective cohort study included eyes with treatment-naïve myopic CNV that achieved complete resolution after initial anti-VEGF therapy. To specifically evaluate the impact of recurrence timing, analyses were restricted to eyes that developed recurrence, which were categorized as early (&lt; 12 months) or late (≥ 12 months). Baseline characteristics, multimodal imaging features, treatment profiles, and recurrence-specific parameters were compared. Longitudinal changes in best-corrected visual acuity (BCVA) were analyzed using linear mixed-effects models, and factors associated with the final BCVA were evaluated using multivariable linear regression.</p> Results <p>Of the 79 eyes, 32 (40.5%) experienced recurrence during the mean follow-up of 36.9 ± 23.7 months (early: 15 eyes; late: 17 eyes). The early recurrence group exhibited a significantly longer axial length (<i>p</i> = 0.019); other baseline features and treatment profiles were similar between groups. At recurrence, subretinal hyperreflective material height was significantly greater in the late recurrence group (<i>p</i> = 0.041). Both groups showed visual improvement after initial treatment, without a significant difference in BCVA at any predefined time point. Baseline BCVA was the only independent predictor for final BCVA (β = 0.46, <i>p</i> = 0.039); no significant association between recurrence timing and visual outcomes was detected.</p> Conclusion <p>Visual outcomes were comparable between early and late recurrences of myopic CNV. Baseline BCVA was the strongest factor associated with long-term visual outcome, whereas no association between recurrence timing and visual outcomes was detected in this cohort.</p>